OBSN — Obseva SA Share News
0.000.00%
Last trade - 00:00- CH₣0.14m
- -CH₣2.20m
- $19.64m
Brief: Obseva Announces Ind Approval For Yuyuan Bioscience’S Phase 1 Clinical Trial Of Nolasiban In China
Brief: Obseva SA Announces Progress On Restructuring Initiatives
Swiss stocks - Factors to watch on August 22
Brief: Obseva Files Second Quarter 2022 Financial Statements
Swiss stocks - Factors to watch on August 2
ObsEva shares plunge after bankruptcy filing
Brief: Obseva Plans To Initiate A Corporate Restructuring
U.S. STOCKS ON THE MOVE-PayPal Holdings, Alphabet, T-Mobile US
Swiss stocks - Factors to watch on July 27
Brief: Obseva Announces UK MHRA Marketing Authorization For Yselty® (Linzagolix)
Swiss stocks - Factors to watch on May 30
Brief: ObsEva SA Entered Into Waiver & Amendment Agreement
Brief: Obseva Announces Corporate Updates
Brief: Obseva SA Announces That Shareholders Approved All Board Proposals At Its 2022 Annual General Meeting
Swiss stocks - Factors to watch on May 18
Brief: ObsEva Presents Clinical Data On Oral GnRH Antagonist Linzagolix
Swiss stocks - Factors to watch on May 2
Brief: Obseva Announces Confirmation Of Positive CHMP Opinion For Linzagolix, An Oral Gnrh Antagonist, For Treatment Of Uterine Fibroids
Brief: Obseva Announces Additional Efficacy Results For Linzagolix 200 Mg With Add-Back Therapy And Linzagolix 75 Mg Without Abt In Phase 3 Edelweiss 3 Trial In Patients With Moderate-To-Severe Endometriosis-Associated Pain